GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bio Plus Co 099430.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,980

+1.53%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩90.90bn

FY2018FY2025

Net income

₩15.00bn

FY2018FY2025

Free cash flow

−₩33.19bn

FY2018FY2025

Shareholders' equity

₩174.84bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue₩90.90bn₩66.41bn₩65.04bn₩56.72bn₩37.42bn₩24.37bn₩17.02bn₩11.04bn
Gross profit₩60.61bn₩42.64bn₩39.57bn₩33.81bn₩23.65bn₩16.56bn₩11.20bn₩6.66bn
Research and development₩3.39bn₩1.48bn₩1.17bn₩1.08bn₩435.2m₩276.1m——
Operating income₩15.01bn₩23.67bn₩28.03bn₩25.24bn₩16.66bn₩12.33bn₩6.80bn₩3.97bn
Net income₩15.00bn₩14.15bn₩25.58bn₩21.14bn₩10.67bn₩9.70bn₩5.62bn₩2.33bn
Diluted earnings per share243.77251.34447.31364.86190.43174.38101.0641.82

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets₩285.04bn₩264.30bn₩172.81bn₩146.52bn₩88.46bn₩37.94bn₩21.00bn₩13.28bn
Cash and short-term investments—₩41.67bn₩65.00bn₩78.95bn₩41.03bn₩15.99bn₩2.85bn₩4.48bn
Total liabilities₩90.06bn₩116.56bn₩34.75bn₩33.25bn₩9.76bn₩9.42bn₩3.15bn₩5.91bn
Debt₩4.29bn₩4.75bn₩8.77bn₩6.20bn₩369.3m₩38.1m₩45.8m₩4.49bn
Shareholders' equity₩174.84bn₩133.49bn₩127.82bn₩113.27bn₩78.70bn₩28.52bn₩17.85bn₩7.37bn
Shares outstanding62m56m57m58m56m56m56m56m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations₩14.74bn₩22.29bn₩16.04bn₩13.36bn₩13.35bn₩10.04bn₩4.96bn₩3.15bn
Capital spending−₩47.93bn−₩96.65bn−₩21.57bn−₩6.69bn−₩15.36bn−₩1.10bn−₩6.51bn−₩735.6m
Free cash flow−₩33.19bn−₩74.36bn−₩5.53bn₩6.67bn−₩2.01bn₩8.95bn−₩1.55bn₩2.41bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩25.40bn₩26.51bn₩23.18bn₩24.06bn₩20.67bn₩22.98bn₩29.09bn₩16.42bn
Gross profit₩17.42bn₩18.22bn₩14.88bn₩17.56bn₩13.04bn₩15.14bn₩21.22bn₩9.70bn
Operating income₩6.25bn₩5.65bn₩962.6m₩5.55bn₩2.07bn₩7.10bn₩4.19bn₩4.72bn
Net income₩2.03bn₩6.69bn₩2.00bn₩3.12bn₩2.18bn₩7.69bn₩3.05bn₩3.28bn
Diluted earnings per share33.05108.6832.5550.7137.08131.5153.8558.26
Cash from operations₩1.39bn₩5.33bn₩3.98bn₩3.60bn₩1.44bn₩5.71bn₩22.29bn₩17.47bn
Capital spending−₩2.33bn−₩2.74bn−₩8.90bn−₩6.13bn−₩14.15bn−₩18.75bn−₩96.65bn−₩69.40bn
Free cash flow−₩932.0m₩2.59bn−₩4.91bn−₩2.52bn−₩12.71bn−₩13.05bn−₩74.36bn−₩51.93bn
Total assets₩296.60bn₩297.50bn₩285.04bn₩293.47bn₩271.36bn₩278.01bn₩264.30bn₩248.43bn
Cash and short-term investments—————₩29.01bn₩41.67bn₩69.04bn
Debt₩13.57bn₩14.16bn₩4.29bn₩3.61bn₩1.92bn₩4.66bn₩4.75bn₩4.57bn
Shareholders' equity₩178.44bn₩177.55bn₩174.84bn₩170.61bn₩154.36bn₩150.21bn₩133.49bn₩129.46bn

Financial ratios

Data as of 2 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin66.7%64.2%60.8%59.6%63.2%68.0%
Operating margin16.5%35.6%43.1%44.5%44.5%50.6%
Net margin16.5%21.3%39.3%37.3%28.5%39.8%
Return on equity8.6%10.6%20.0%18.7%13.6%34.0%
Return on assets5.3%5.4%14.8%14.4%12.1%25.6%
Revenue growth36.9%2.1%14.7%51.6%53.6%43.2%
Earnings growth6.0%-44.7%21.0%98.0%10.0%72.5%
Current ratio0.84x0.68x8.88x11.19x7.26x2.76x
Debt to equity0.02x0.04x0.01x0.05x0.00x0.00x
Equity ratio61.3%50.5%74.0%77.3%89.0%75.2%
Interest coverage49.42x89.84x465.08x1897.43x31.95x211.95x
R&D as a share of sales3.7%2.2%1.8%1.9%1.2%1.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue17.0%30.1%—
Operating income-15.9%4.0%—
Net income-10.8%9.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin65.6%63.3%63.6%—
Operating margin24.6%32.9%35.5%—
Net margin18.5%27.2%28.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings20.629.115.419.036.1
Price to sales3.46.26.07.110.3

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2022
Paid in the year120.0070.0070.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.